Deepbridge Capital

"Spotlight Pathology represents exactly the type of highly innovative company that Deepbridge is privileged to invest in. We initially supported the team through our Seed Enterprise Investment Scheme (SEIS), and are now pleased to back them again through our EIS fund, alongside EHE and Lyva Labs. We look forward to supporting the team as they scale in the exciting field of digital pathology."

"Our mission at Microplate Dx is to improve the quality of lives for patients by providing antimicrobial stewardship cost-effectively. Any delay in identifying the correct antibiotic for treatment can put lives at risks and huge pressure on clinical decision making, especially when the antibiotic sensitivity data that Microplate Dx can produce in an hour or less compared to the current approach that can take two days using existing techniques."

"With the increasing demand from semiconductor businesses for 'second-sourcing' to unlock new markets and address evolving requirements, Thalia stands as the ideal strategic partner. Our AMALIA platform provides a proven solution that enables them to, for example, quickly and efficiently migrate existing designs into the sub-20 nanometre range to align with industry demand for better performance and power consumption."

"The single photon source developed by Aegiq represents a platform technology with unparalleled specifications that enables various applications. As a photonics guy, I am more than thrilled to invest here and support the highly skilled team on their journey,"

"There are over three million dialysis patients worldwide and every year patients undergo nearly 650,000 surgical AVF creation procedures. However, these procedures take a long time to heal and are prone to failure. Our technology has the power to significantly improve the outcomes for dialysis patients, improving their quality of life and saving millions of pounds in the process. We are delighted to have the support of BGF and Parkwalk to help the business move forward with our clinical trials and ultimately roll-out this ground-breaking product to a global market."

"We have been delighted with our progress to date and the significant interest in our technologies from major players in our sector. This next stage of development will see the Company expand on these exciting relationships whilst continuing our product development."

"Glyconics offers a transformational, cost-efficient, rapid and non-invasive approach to diabetes screening – and it is testament to this pioneering device and all at Team Glyconics that this raise was so significantly over-subscribed. We are delighted to be continuing with our existing investors and, of course, welcome our new investors from Wealth Club and other private investors to the fold."

"We are very focused on ensuring our software helps both our corporate clients and our host venues create greater efficiencies within the increasingly complex event booking process. This is why, during the pandemic, we beat traditional agency incumbents to win significant multi-year contracts from FTSE 100 companies in the media, professional services and FMCG sectors."

"As market practitioners we have always been acutely aware of market developments and working with market participants to shape our product development and innovation. As such it was important, we found a partner who shared our vision within financial services. We believe that Toscafund’s global expertise and impressive market connectivity will be of tremendous benefit to VoxSmart in our next stage of growth."

"I am delighted and look forward to working with Martin. We both share the passion for growing businesses which make a difference in people’s lives. These are exciting times as we forge our plans for Zilico"

"We are delighted that Deepbridge has continued to support our future development."

"This new and substantial investment from Deepbridge will enable Touch Biometrix to build upon its development work with the aim of defining its first minimum viable product ahead of scaled product in early 2020."